3D cardiac tissues for drug discovery

Cardiovascular diseases are the N°1 cause of death worldwide. Currently, the majority of cardiac diseases cannot be prevented nor cured, as new cardiovascular drugs do not reach the patients due to a failure rate of 91.8% in clinical trials. The problem is that the commonly used animal and 2D in vitro models for drug discovery and development do not reliably mimic the complex human heart function, and consequently provide insufficient insights in human disease mechanisms. River BioMedics aims to increase the number of novel drugs that reach the patients, by increasing cardiac drug success rates in clinical trials. River BioMedics is the first company to provide highly human predictive in vitro 3D heart models that are suitable for high-throughput compound screening during drug validation and discovery. We will use a hybrid business model by both selling ready-to-use assay plates, as well as performing drug discovery services in-house to pharmaceutical and biotech companies. If granted, the Take-off 2 will allow us to bring our high-throughput 3D cardiac assay to market the next 2 years.

  • Projectnummer / Project number: 18328
  • Deelnemende kennisinstellingen / Participating institutes: University of Twente
  • Projectleider / Project leader: A. Gunkel, Magneto B.V.
  • Type project / Type project: Lopend / Current
  • Startdatum / Start date: 01-01-2020
  • Programma / Programme: Take-off
  • Vakgebied / Discipline: Technische wetenschappen / Engineering sciences